EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study

Takafumi Aritomi, Koshiro Sonomoto iD, Shingo Nakayamada, Hiroaki Tanaka, Atsushi Nagayasu, Satoshi Kubo iD, Ippei Miyagawa, Ayako Yamaguchi, Naoaki Ohkubo, Yasuyuki Todoroki iD, Yurie Satoh-Kanda, Masanobu Ueno iD und 19 weitere

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70125 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Takafumi Aritomi und 30 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Biological Products, Bone Density. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: University of Occupational and Environmental Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real‐world study showed that one‐year b/tsDMARDs use did not arrest osteoporosis progression. This study aimed to examine longer‐term changes in bone mineral density (BMD).

Methods

BMD was observed for up to five years in patients receiving b/tsDMARDs for active RA. The primary endpoint was change in BMD (T score), and the secondary endpoint was change in T score–related factors.

Results

In total, 797 patients (antiosteoporosis–, n = 645; antiosteoporosis+, n = 152) were included, with a median 3.1‐year follow‐up (2,489 patient‐years). Clinical Disease Activity Index (CDAI) improved in both groups (antiosteoporosis– 26.0 to 6.6; antiosteoporosis+ 24.4 to 6.8). T scores decreased significantly in the femoral neck and radius in the antiosteoporosis− group but not in the antiosteoporosis+ group (antiosteoporosis–: mean change –0.11 to –0.33, both P < 0.001; antiosteoporosis+ –0.01 to –0.10, P = 0.830 and 0.071, respectively). Overall, 460 patients (58%) experienced a decrease in T score. A high baseline T score correlated with a subsequent decrease, whereas longer osteoporosis treatment duration correlated with an increase. Unexpectedly, the duration of b/tsDMARD use and mean CDAI during observation were not associated with BMD maintenance.

Conclusion

Even when RA activity was controlled with b/tsDMARDs, BMD still decreased. This study emphasizes the importance of considering osteoporosis as an independent aspect of RA, beyond inflammation control. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidBiological ProductsBone DensityOsteoporosisAdultAgedFemaleHumansMaleMiddle AgedDisease ProgressionFemur NeckMethotrexate

Substanzen

Antirheumatic AgentsBiological ProductsMethotrexate

Autor:innen und Institutionen

  • First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan.
  • Department of Laboratory and Transfusion Medicine, Hospital of the University of Occupational and Environmental Health Japan, Kitakyushu, Japan.
  • Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health Japan, Kitakyushu, Japan.
  • Department of Rheumatology, Shunan Memorial Hospital, Kudamatsu, Japan.
  • Department of Rheumatology, Saiseikai Yahata General Hospital, Kitakyushu, Japan.
  • Department of Medical Informatics and Management, Hospital of the University of Occupational and Environmental Health Japan, Kitakyushu, Japan.

ORCID-Profile: Koshiro Sonomoto, Satoshi Kubo, Yasuyuki Todoroki, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Yusuke Miyazaki, Yoshiya Tanaka

Förderung

  • University of Occupational and Environmental Health

Zitieren

APA

Aritomi, T., Sonomoto, K., Nakayamada, S., Tanaka, H., Nagayasu, A., Kubo, S., Miyagawa, I., Yamaguchi, A., Ohkubo, N., Todoroki, Y., Satoh-Kanda, Y., Ueno, M., Kanda, R., Fujita, Y., Funada, M., Sakai, H., Matsunaga, S., Tanaka, H., Shinojima, M., …, & Tanaka, Y. (2026). Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.70125

Vancouver

Aritomi T, Sonomoto K, Nakayamada S, Tanaka H, Nagayasu A, Kubo S, et al. Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study. Arthritis & Rheumatology. 2026. doi:10.1002/art.70125

BibTeX
@article{Aritomi2026,
  author = {Aritomi, Takafumi and Sonomoto, Koshiro and Nakayamada, Shingo and Tanaka, Hiroaki and Nagayasu, Atsushi and Kubo, Satoshi and Miyagawa, Ippei and Yamaguchi, Ayako and Ohkubo, Naoaki and Todoroki, Yasuyuki and Satoh-Kanda, Yurie and Ueno, Masanobu and Kanda, Ryuichiro and Fujita, Yuya and Funada, Masashi and Sakai, Hidenori and Matsunaga, Satsuki and Tanaka, Hiroaki and Shinojima, Masayuki and Kawamura, Hiroki and Takahashi, Kazuki and Ando, Miyabi and Haru, Kazuki and Miyazaki, Yusuke and Hanami, Kentaro and Nawata, Masao and Fukuyo, Shunsuke and Nakatsuka, Keisuke and Tokunaga, Mikiko and Saito, Kazuyoshi and Tanaka, Yoshiya},
  title = {Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70125}
}
Kostenlos starten →